ABV-1504 Drug Market
"ABV-1504 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about ABV-1504 for Major Depressive Disorder (MDD) in the seven major markets. A detailed picture of the ABV-1504 for MDD in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the ABV-1504 for MDD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ABV-1504 market forecast analysis for MDD in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in MDD.
ABV-1504 Drug Summary
California-based American BriVision is a biopharma and medical device company developing therapies for a range of conditions focused on oncology/hematology, CNS, and ophthalmology. The active ingredient of ABV-1505, ABV-1504, and ABV-1601 is PDC-1421, which is a botanical investigational new drug (IND).
Through its subsidiary BioLite, ABVC has completed a Phase II study of the PDC-1421 capsule to evaluate its safety and efficacy in treating patients with MDD. The study, conducted at Stanford University, found the PDC-1421 capsule to be safe and well-tolerated in effectively treating six enrolled adult patients. Both low and high doses of the PDC-1421 capsule passed the required 40% population in ADHD-RS-IV test scores, thus meeting the study’s primary end points.
The percentages of improvement on the adult attention-deficit/hyperactivity disorder rating scale score from baseline through 8 weeks of treatment were 83.3% in the Intention-To-Treat (ITT) population and 80.0% in the per-protocol (PP) population, which supports the further clinical development of ABV-1505/PDC-1421 for the treatment of adult ADHD and MDD.
Scope of the ABV-1504 Drug Market Report
The report provides insights into:
• A comprehensive product overview including the ABV-1504 description, mechanism of action, dosage and administration, research and development activities in MDD.
• Elaborated details on ABV-1504 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ABV-1504 research and development activities in MDD across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ABV-1504.
• The report contains forecasted sales of ABV-1504 for MDD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for MDD.
• The report also features the SWOT analysis with analyst views for ABV-1504 in MDD.
ABV-1504 Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ABV-1504 Analytical Perspective by DelveInsight
• In-depth ABV-1504 Market Assessment
This report provides a detailed market assessment of ABV-1504 for MDD in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data of ABV-1504.
• ABV-1504 Clinical Assessment
The report provides the clinical trials information of ABV-1504 for MDD covering trial interventions, trial conditions, trial status, start and completion dates.
ABV-1504 Drug Report Highlights
• In the coming years, the market scenario for MDD is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ABV-1504 dominance.
• Other emerging products for MDD are expected to give tough market competition to ABV-1504 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ABV-1504 in MDD.
• Our in-depth analysis of the forecasted sales data of ABV-1504 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ABV-1504 in MDD.
Key Questions
• What is the product type, route of administration and mechanism of action of ABV-1504?
• What is the clinical trial status of the study related to ABV-1504 in MDD and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ABV-1504 development?
• What are the key designations that have been granted to ABV-1504 for MDD?
• What is the forecasted market scenario of ABV-1504 for MDD?
• What are the forecasted sales of ABV-1504 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ABV-1504 for MDD?
• Which are the late-stage emerging therapies under development for the treatment of MDD?
